About this trial
Patient Profile
Unresectable hepatocellular carcinoma
Where’s this trial being run?
St Vincents University Hospital and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK7902-002/E7080-G000-311/LEAP-002 |
|---|---|
| Number: | CTRIAL-IE 18-43 |
| Full Title: | Phase 3 randomized, double-blinded, active-controlled clinical study to evaluate the safety and efficacy of lenvatinib in combination with pembrolizumab versus lenvatinib alone in first-line intervention of participants with unresectable hepatoceullar carcinoma |
| Principal Investigator: | Ray McDermott |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | MSD |
| Recruitment Started: |
Global: Ireland: 10 |
| Global Recruitment Target: | 750 |
|---|---|
| Ireland Recruitment Target: |